Last reviewed · How we verify

NCT04009005

Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis

Active, enrolled NA Last updated 26 December 2025
What this trial tests

NA trial testing Therapeutic diet and lifestyle in Clinically Isolated Syndrome in 44 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 May 2020
Primary endpoint
1 August 2022
1 September 2027

Quick facts

Lead sponsorTerry L. Wahls
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment44
Start date1 May 2020
Primary completion1 August 2022
Estimated completion1 September 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Terry L. Wahls

Who can join

Adults 18 to 55, any sex, with Clinically Isolated Syndrome or Relapsing Remitting Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A key question in efforts to reduce symptoms and improve quality of life for multiple sclerosis (MS) patients is whether a therapeutic lifestyle (diet, stress reduction and exercise) is inferior to disease-modifying drug treatments in terms of reducing multiple sclerosis related symptoms, improving function and quality of life. This study will prospectively assess the changes in quality of life and clinical outcomes in two cohorts of patients who are recently diagnosed with clinically isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS) to begin answering that question. The goal of this project is to compare a diet and therapeutic lifestyle only treatment usual care in the setting of newly diagnosed individuals with RRMS or CIS, which is the precursor to the development of MS. Due to the COVID 19 Pandemic, the study was redesigned from an in-person study to a virtual visit only study prior to enrolling study subjects.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Effects of a Remote Multimodal Intervention Involving Diet, Walking Program, and Breathing Exercise on Quality of Life Among Newly Diagnosed People with Multiple Sclerosis: A Quasi-Experimental Non-Inferiority Pilot Study.
    Saxby SM, Shemirani F, Crippes LJ, Ehlinger MA, et al · · 2024 · cited 4× · PMID 38222092 · DOI 10.2147/dnnd.s441738
  2. Feasibility and assessment of self-reported dietary recalls among newly diagnosed multiple sclerosis: a quasi-experimental pilot study.
    Saxby SM, Ehlinger MA, Brooks L, Titcomb TJ, et al · · 2024 · cited 1× · PMID 39464680 · DOI 10.3389/fnut.2024.1369700

Verify or expand the search:

Other recruiting trials for Clinically Isolated Syndrome

Currently open trials in the same condition.

Other Terry L. Wahls trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04009005.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing